Trial Profile
Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Recombinant staphylokinase Supergene (Primary) ; Tenecteplase
- Indications Myocardial infarction
- Focus Registrational; Therapeutic Use
- Acronyms FORMAT-1; FRIDOM1
- Sponsors Supergene
- 03 Dec 2014 New trial record